Objective: To observe the clinical curative effect of Bazhen Granule assisted with Fluorouracil+Pirarubicin+Oxaliplatin in treatment of advanced gastric cancer and its influences on cellular immunity index and the expressions of P53 protein and interleukin-6 (IL-6). Methods: 80 patients with advanced gastric cancer were randomly divided into two groups, 40 cases in control group were given Fluorouracil+Pirarubicin+Oxaliplatin treatment, 40 cases in study group were given Bazhen Granule on the basis of the control group, the two groups were treated for 2 courses continuously, each course was 3 weeks. The clinical efficacy of the two groups after treatment was compared, the cellular immunity index and the expressions of P53 protein and interleukin-6 were detected in two groups before and after treatment, the incidence of adverse reactions during the treatment of the two groups was statistically analyzed. Results:The total effective rate of clinical treatment in the study group was 67.50%, which was significantly higher than 40.00% in the control group (P<0.05); after treatment, the levels of CD3+, CD4+, CD4+/CD8+ and NK cell in the two groups were significantly higher than those before treatment (P<0.05), and CD8+ levels were significantly lower than those before treatment (P<0.05), the levels of CD3+, CD4+, CD8+, CD4+/CD8+ and NK cell in the study group were better than those in the control group (P<0.05); after treatment, the levels of P53 protein and IL-6 in the two groups were significantly lower than those before treatment (P<0.05), the levels of serum P53 protein and IL-6 in the study group were significantly lower than those in the control group (P<0.05). The incidence rate of adverse reactions in the study group during the treatment was significantly lower than that in the control group (P<0.05). Conclusion:The clinical curative effect of Bazhen Granule assisted with Fluorouracil+Pirarubicin+Oxaliplatin in treatment of advanced gastric cancer is significant, it can significantly improve the cellular immunity index, reduce the expression level of P53 protein and IL-6.
 GABBERT H E,MVLLER W,SCHNEIDERS A,et al.The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma[J].Cancer,2015,76(5):720-726.
 GARRIDO M,FONSECA P J,VIEITEZ J M,et al.Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer[J].Expert Rev Anticancer Ther,2014,14(8):887-900.
 NAKAMURA A,NAKAJIMA G,OKUYAMA R,et al.Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase[J].Gastric Cancer,2014,17(1):188-195.
 VAN C E,BONI C,TABERNERO J,et al.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer:a randomized phase Ⅱ study[J].Ann Oncol,2015,26(1):149-156.